This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Essential 2012 Biotech Stock Fall Preview

Clinical trial results: A jam-packed calendar.

The list of companies with clinical trials expected to read out data before year-end is staggeringly long. The outcomes of these studies, more than anything else, may determine how the entire biotech sector ends 2012. Nothing moves a biotech stock -- up or down -- like important clinical trial data.

Phase III studies, all expecting results before the year ends: Amicus Therapeutics' (FOLD) Amigal in Fabry disease; Biogen Idec's rFactor VIII for hemophilia A, rFactor IX for hemophilia B and dexpramipexole for amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease and Biomarin Pharmaceuticals' (BMRN) GALNS for MPS IV also known as Morquio Syndrome.

More phase III studies: Acadia Pharmaceuticals' (ACAD) pimavanserin in Parkinson's psychosis; Celsion's (CLSN - Get Report) Thermodox in liver cancer; Clovis Oncology's (CLVS) CO-101 for pancreatic cancer; Ziopharm's (ZIOP) palifosfamide for sarcoma; Celgene's (CELG) Abraxane in melanoma and pancreatic cancer; and Exact Sciences' (EXAS) Cologuard for colon cancer detection.

Like I said, a long list!

Some of the most impactful clinical data this fall will likely come from companies presenting updates of studies that have already been presented and caused a stir on Wall Street. Topping this list is Sarepta Therapeutics (SRPT - Get Report), which will be presenting additional (48 week) data from its eteplirsen muscular dystrophy study at the World Muscle Society meeting, Oct. 9-13.

Vertex Pharmaceuticals (VRTX) will be a headliner at the cystic fibrosis meeting Oct. 11-13 with a detailed data presentation on the combination of Kalydeco and VX-809. Gilead Sciences (GILD) is expected to present early "cure rate" data on its all-oral hepatitis C combination therapy of GS-7977 and GS-5885 at the AASLD Liver Meeting in November. Celldex Therapeutics (CLDX) will present updated results from a phase II study of its immunotherapy CDX-011 at the San Antonio Breast Cancer Symposium in December. Threshold Pharmaceuticals (THLD) should have survival data from the previously reported phase II study of TH-302 in pancreatic cancer.

A more complete list of clinical trials with looming data releases can be read here.

Drug launches and other questions: Overlook at your peril.

The most important "other question" in 2012 is the resolution of New Chemical Entity (NCE) status for Amarin's (AMRN) Vascepa. Amarin is winning new patents for the prescription fill oil pill but still needs the market exclusivity that comes with NCE status. The next update is expected on Sept. 14.
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARIA $7.18 0.00%
AMRN $1.83 0.00%
CLSN $1.48 0.00%
EXEL $4.61 0.00%
SRPT $14.19 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs